All Articles

A tiny 0.12% stake disclosure seems trivial, but it offers a masterclass in reading M&A signals—a vital skill for investors in any sector.

Bicara Therapeutics' latest data for its dual-action antibody shows impressive consistency, de-risking its pivotal trial for a tough head and neck cancer.

After past stumbles, Merck unveils two new Alzheimer's candidates targeting different pathways, a high-stakes bet signaling a major strategic shift.

EnviroGold Global is deploying mobile pilot plants to unlock trillions in mine tailings. Is this strategic pivot the key to dominating the green metals race?

In the shadow of giants, a junior miner uses advanced geophysics to de-risk its hunt for a major discovery in the prolific Vicuña District.

How one skincare brand's new SPF, blending biotech and strict safety standards, reveals a powerful business strategy for winning in today's market.

A therapeutic footwear expert is stepping into the rugged $42B outdoor market. Can FitVille's focus on comfort and accessibility disrupt established giants?

A perfect storm of provider fee waivers and new tax credits is finally making 401(k)s affordable for small businesses, reshaping the battle for talent.

Mobix Labs posts a 54% revenue jump and slashes losses, but a volatile stock and aggressive M&A strategy raise questions about its long-term stability.

Fermi America's 11GW Texas energy campus will power AI, but its success hinges on an innovative hybrid cooling tech designed to protect a vital aquifer.

Youdao's 2025 Word of the Year reveals more than a search trend; it shows a nation's collective shift towards embracing an AI-powered future.

The appointment of a CNBC digital veteran to lead CoinDesk signals a pivotal shift. What does this mean for the future of crypto information and investment?

With FDA Breakthrough status, Ionis's olezarsen could transform care for millions with a dangerous lipid disorder by preventing life-threatening pancreatitis.

Akebia Therapeutics expands its pipeline, targeting rare kidney diseases with two novel drugs and offering new hope where treatment options are scarce.

A key investor sells John Wood Group shares below the approved takeover price. We decode the move and what it means for the engineering firm's future.

Clean Energy Fuels' new RNG facility turns farm waste into a carbon-negative asset, revealing a powerful strategy for institutional investors.

A private equity-backed firm is offering a 'Fortune 500' toolkit to save local auto shops. But does this empowerment come at the cost of independence?

CerraCap Ventures and Impact VC have merged, creating a new firm built on corporate access. Is this integrated model the future of startup acceleration?

With a $50M Series A, Morphocell Technologies is advancing its revolutionary ReLiver® therapy, aiming to replace organ transplants with off-the-shelf tissue.

With robust economics and U.S. government support, a New York mine is set to become a cornerstone of America's critical mineral independence strategy.